InvestorsHub Logo
Followers 828
Posts 119319
Boards Moderated 16
Alias Born 09/05/2002

Re: None

Saturday, 07/23/2011 12:35:16 PM

Saturday, July 23, 2011 12:35:16 PM

Post# of 149
FDA approves Xeomin, a competitor to MRX’s Dysport:

#msg-65423443

From a technical standpoint, Xeomin is an excellent product, superior to both Botox and Dysport; hence, the limiting factor on Xeomin’s attaining market share is Merz’s low-key marketing (compared to AGN and MRX) and the brand-name loyalty of Botox and Dysport users.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”